Pure Biologics (WAR:PUR) Other Financing: zł4.35 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:PUR Pure Biologics SA WAR:PUR
21 GF Score
Price zł2.16
! 2 Warning Signs
View Full Analysis

What is Pure Biologics Other Financing?

Pure Biologics WAR:PUR +0.23% 21 Other Financing is zł4.35 Mil as of Mar. 2026. GuruFocus rates WAR:PUR with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Pure Biologics's Other Financing for the three months ended in Mar. 2026 was zł0.00 Mil.

Pure Biologics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was zł4.35 Mil.

Pure Biologics Other Financing Historical Data

* Premium members only.

The historical data trend for Pure Biologics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pure Biologics Other Financing Chart

Pure Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.23 -0.33 0.00 -0.29 -0.03

Pure Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 0.29 -0.01 4.07 0.00
WAR:PUR
21GF Score
Pure Biologics SA WAR:PUR
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pure Biologics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł4.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of zł4.35 Mil mean?
Pure Biologics (WAR:PUR) has a Other Financing of zł4.35 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Pure Biologics and its competitors.
Is Pure Biologics' Other Financing too high?
Pure Biologics' current Other Financing is zł4.35 Mil. Overall, Pure Biologics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Pure Biologics' Other Financing compare to VRTX and REGN?
Pure Biologics' Other Financing of zł4.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Pure Biologics and its competitors. Pure Biologics's current Other Financing is zł4.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pure Biologics stock overvalued right now?
Pure Biologics (WAR:PUR) has a current Other Financing of zł4.35 Mil. The current Other Financing is zł4.35 Mil. Pure Biologics' overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Pure Biologics (WAR:PUR), the current Other Financing is zł4.35 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pure Biologics Business Description

Address ul. Dunska 11, Wroclaw, POL, 54-427
Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.
21GF Score

Get the complete analysis for WAR:PUR

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł2.16
Price